PACIRA BIOSCIENCES, INC. Disposal Group, Including Discontinued Operation, Operating Expense
PACIRA BIOSCIENCES, INC. (PCRX) reported Disposal Group, Including Discontinued Operation, Operating Expense of $292.00 thousand for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-07.
Discontinued › Expense Statement › Operating Expenses
us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense · last filed 2020-05-07
- PACIRA BIOSCIENCES, INC. disposal group, including discontinued operation, operating expense for the quarter ending 2020-03-31 was $292.00K, a 311.27% increase year-over-year.
- PACIRA BIOSCIENCES, INC. disposal group, including discontinued operation, operating expense for the quarter ending 2019-12-31 was -$1.38M, a 520.73% decline year-over-year.
- PACIRA BIOSCIENCES, INC. disposal group, including discontinued operation, operating expense for the quarter ending 2019-09-30 was $328.00K, a 12.53% decline year-over-year.
- PACIRA BIOSCIENCES, INC. disposal group, including discontinued operation, operating expense for the quarter ending 2019-06-30 was $229.00K, a 34.38% decline year-over-year.
- PACIRA BIOSCIENCES, INC. disposal group, including discontinued operation, operating expense for fiscal 2019 was -$752.00K, a 153.64% decline from fiscal 2018.
- PACIRA BIOSCIENCES, INC. disposal group, including discontinued operation, operating expense for fiscal 2018 was $1.40M, a 4.43% decline from fiscal 2017.
- PACIRA BIOSCIENCES, INC. disposal group, including discontinued operation, operating expense for fiscal 2017 was $1.47M.
| Period end | Disposal Group, Including Discontinued Operation, Operating Expense 3 month | Disposal Group, Including Discontinued Operation, Operating Expense 6 month | Disposal Group, Including Discontinued Operation, Operating Expense 9 month | Disposal Group, Including Discontinued Operation, Operating Expense 12 month |
|---|---|---|---|---|
| 2020-03-31 | $292.00K 10-Q · filed 2020-05-07 | -$1.09M derived: sum of 2 quarters · filed 2020-05-07 | -$760.00K derived: sum of 3 quarters · filed 2020-05-07 | -$531.00K derived: sum of 4 quarters · filed 2020-05-07 |
| 2019-12-31 | -$1.38M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | -$1.05M derived: sum of 2 quarters · filed 2020-02-21 | -$823.00K derived: sum of 3 quarters · filed 2020-02-21 | -$752.00K 10-K · filed 2020-02-21 |
| 2019-09-30 | $328.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $557.00K derived: sum of 2 quarters · filed 2019-11-08 | $628.00K 10-Q · filed 2019-11-08 | $956.00K derived: sum of 4 quarters · filed 2020-02-21 |
| 2019-06-30 | $229.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $300.00K 10-Q · filed 2019-08-08 | $628.00K derived: sum of 3 quarters · filed 2020-02-21 | $1.00M derived: sum of 4 quarters · filed 2020-02-21 |
| 2019-03-31 | $71.00K 10-Q · filed 2019-05-02 | $399.00K derived: sum of 2 quarters · filed 2020-02-21 | $774.00K derived: sum of 3 quarters · filed 2020-02-21 | $1.12M derived: sum of 4 quarters · filed 2020-02-21 |
| 2018-12-31 | $328.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | $703.00K derived: sum of 2 quarters · filed 2020-02-21 | $1.05M derived: sum of 3 quarters · filed 2020-02-21 | $1.40M 10-K · filed 2020-02-21 |
| 2018-09-30 | $375.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $724.00K derived: sum of 2 quarters · filed 2018-11-01 | $1.07M 10-Q · filed 2018-11-01 | $3.49M derived: sum of 4 quarters · filed 2020-02-21 |
| 2018-06-30 | $349.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $699.00K 10-Q · filed 2018-08-02 | $3.11M derived: sum of 3 quarters · filed 2020-02-21 | |
| 2018-03-31 | $350.00K 10-Q · filed 2018-05-03 | $2.76M derived: sum of 2 quarters · filed 2020-02-21 | ||
| 2017-12-31 | $2.41M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | $1.47M 10-K · filed 2020-02-21 | ||
| 2017-09-30 | -$945.00K 10-Q · filed 2017-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |